Copyright 2018 - Custom text here

Our Treatments

Treatment considerations
Since Lyme disease can become persistent, recurrent and refractory even in the face of antibiotic therapy, evaluation
and treatment must be prompt and aggressive. Although no well designed studies have been carried out, the available data support the prompt use of antibiotics to prevent chronic Lyme disease. Antibiotic therapy may need to be initiated upon suspicion of the diagnosis, even without definitive proof. Neither the optimal antibiotic dose nor the duration of therapy has been standardized, but limited data suggest a benefit from increased dosages and longer treatment, comparable to the data on tuberculosis and leprosy which, are caused by similarly slow-growing pathogens.

Choosing an antibiotic
In acute Lyme disease, the choice of antibiotics should be tailored to the individual and take into account the severity of the disease as well as the patient’s age, ability to tolerate side effects, clinical features, allergy profile, comorbidities, prior exposure, epidemiologic setting and cost. Conversely, persistent and refractory Lyme disease treatment is more likely to include intravenous and/or intramuscular antibiotics. The choices depend in part on the patient’s response to antibiotic therapy and on the success of antibiotics in treating other Lyme disease patients (see below). Therapy usually starts with oral antibiotics, and some experts recommend high dosages. The choice of antibiotic therapy is guided by weighing the greater activity of intravenous antibiotics in the central nervous system against the lower cost and easy administration of oral antibiotics for B. burgdorferi.

Oral antibiotic options
For many Lyme disease patients, there is no clear advantage of parenteral therapy. Along with cost considerations and pressure to treat patients with Lyme disease with the least intervention, there is growing interest in the use of oral therapy. First-line drug therapies for Lyme disease may include (in alphabetical order): oral amoxicillin, zithromycin, cefuroxime, clarithromycin, doxycycline and tetracycline. These antibiotics have similar favorable results in comparative trials of early Lyme disease. In one study, azithromycin performed slightly less well when compared to amoxicillin and doxycycline. However, the efficacy of azithromycin was underestimated because the antibiotic was only given for 10 days.
One study has suggested that oral doxycycline (100 mg twice daily for 30 days) is as effective as intravenous ceftriaxone (2 g daily for 30 days) in early disseminated Lyme disease. Two European studies have demonstrated similar efficacy of oral doxycycline and parenteral penicillin and ceftriaxone in early Lyme disease.
There are no studies comparing oral with intravenous antibiotics for persistent, recurrent and refractory Lyme disease.

Intravenous antibiotic options
It is common practice to consider intravenous antibiotics upon failure of oral medications in patients with persistent, recurrent or refractory Lyme disease, and as the first line of therapy for certain conditions, (i.e., encephalitis, meningitis, optic neuritis, joint effusions and heart block).
Ideally, the intravenous antibiotic should be selected on the basis of in vitro sensitivity testing or clinical experience. Intravenous antibiotics are also justified by concern for penetration into the central nervous system.
Until recently, ceftriaxone, cefotaxime and penicillin were the only intravenous antibiotics routinely studied for use in Lyme disease. Intravenous imipenem, azithromycin and doxycycline have an adequate antispirochetal spectrum of activity and may represent suitable alternative therapies. However, the latter two drugs are often considered for intravenous use only if they are not tolerated orally.
There is a paucity of data on alternative intravenous antibiotics, and their success is less predictable in chronic Lyme disease.

Intramuscular antibiotic options
Intramuscular benzathine penicillin (1.2 to 2.4 million units per week) is sometimes effective in patients who do not respond to oral and intravenous antibiotics. If intramuscular benzathine penicillin is used, long-term therapy may be necessary due to the low serum concentration of this form of penicillin. Luft and colleagues report, “It was demonstrated that while B. burgdorferi may be sensitive to relatively small concentrations of penicillin and ceftriaxone, the organism is killed slowly. This implies that, as in syphilis, prolonged blood levels of these drugs may be necessary in order to ensure cure”.
One-third of a chronic Lyme disease population responded to intramuscular benzathine penicillin (1.2 to 2.4 million units per week). Benzathine penicillin has mainly been used in patients who have had multiple relapses while receiving oral or intravenous antibiotic therapy or who are intolerant of oral or intravenous antibiotics.

Combination antibiotic treatment
Combination therapy with two or more antibiotics is now increasingly used for refractory Lyme disease and has also been given as initial therapy for some chronic presentations.

This approach is already used for another tickborne illness, babesiosis . Oral amoxicillin, cefuroxime or (more
recently) cefdinir combined with a macrolide (azithromycin or clarithromycin) are examples of combination regimens that have proven successful in clinical practice, although controlled clinical trials are lacking in persistent, recurrent and refractory Lyme disease.

Combination therapy in patients with Lyme disease raises the risk of adverse events. This risk must be weighed against the improved response to combination therapy in Lyme disease patients failing single agents.

Sequential treatment
Clinicians increasingly use the sequence of an intravenous antibiotic followed by an oral or intramuscular antibiotic. In two recent case series that employed combination therapy and sequential therapy, most patients were successfully treated. A logical and attractive sequence would be to use intravenous therapy first (e.g., intravenous ceftriaxone), at least until disease progression is arrested and then follow with oral therapy for persistent and recurrent Lyme disease.

Treatment for Persistent Lyme Disease

The CDC clinical criteria for Lyme disease exists for the purpose of monitoring the rate of Lyme disease nationally and is quite narrowly defined in order to ensure a high degree of specificity in the diagnosis. Although the CDC recognizes that Lyme encephalopathy exists, encephalopathy is not part of the surveillance case definition. Hence, physicians who rely on the narrow surveillance case criteria of the CDC for clinical diagnosis will fail to diagnose some patients who in fact do have Lyme disease and the patient's treatment will either not occur or will be delayed. Such delay in treatment may result in an acute treatable illness becoming a chronic less responsive one.

Our treatment protocol:

Our therapeutic approach is designed to be used in patients affected by chronic Lyme disease that are characterized by progressive worsening, very symptomatic, with poor quality of life. It is built to compliment previous treatments in a holistic way, not interfering with previous approaches, but interfering directly; in the patient’s quality of life, improving and modifying the natural course of the disease, by immune modulating the antibody response and eliminating any bacteria, parasites or viruses in the blood stream, using UV light and applying natural antiseptics like Ozone and H2O2, red cell exchanges and a comprehensive antibiotic/parasitic cycle. Dr. Morales and his staff have been pleased to note that with their work of providing life-altering therapeutic intervention, their patients' quality of life is often restored. In the process, much has been learned about treatment methods and treatment response.


This review
Describes the experience with the development of a novel form of immuno-therapy that represents the first practical and effective means of performing antigent-loaded dendritic cell immuno-therapy, against infections in red blood cells.


Stimulating the immune system
To fight parasites and microorganisms that infect the red blood cells such as, Viruses, bacterias, yeasts and other foreign invaders.

Dendritic Cells

Pulsed with infected red blood cells, peptide components, induce anti-infection immunity.

Extracorporeal photopheresis with ultraviolet light theraphy (UV-B, UV-A and C.)

Mononuclear and disinfected red cells are obtained by extracorporeal photopheresis, then incubated with IL-4 and GM-CSF. (colony stimulating factors).




The electromagnetic spectrum of ultraviolet radiation

The method

Upon exposure to UVA light, covalent crosslinking of RNA or DNA of the cells occurs.

This ultimately results in the proliferative arrest of the treated infected cells.


Mononuclear cells (dendritic cells) are pulsed with the patient's own infected red cells, using fragmented peptides, to induce anti-infection immunity.

This biological product will be returned to the patient as a vaccine against infected red cells.

The photo dynamic therapy, inducing cell maturation.

The passage of the cells through UV light will convert them to mature and educated dendritic cells. (DCs)

How this works:

Upon exposure to UVA light with our special photo sensitizer agent , covalent  of DNA occurs. This results in the proliferative arrest of the treated cells and programs cell death (apoptosis).





Stimulating the immune system:

The generation of an effective T cell-mediated immune response requires the activation of both the cytotoxic (CD8+) and the helper (CD4+)T lymphocyte subsets.






Stimulating the immune system

Injection of growth factors, combined with antigens in vivo, will attract autologous DCs to the immunization site where they will uptake the injected antigens.








Stimulating the immune system:
In light of these findings, the combination of extracorporeal photopheresis, red cells exchange, and immunizations with autologous dendritic cells cultured ex vivo, propelled with infected red blood cells antigens, is a wonderful strategy to elicit a strong immune response in these patients.

f t g

Lyme Clinic Mexico


Avenida Los Tules #140 Col. Diaz Ordaz
Puerto Vallarta:     (912) BIO-MED1
Us and Canada:     (912)-246-6331                   
Internationally:   001-912-246-6331
México:                 01 322 2936161


Dr. Raul Morales, American Society of Hematology, certified Hematologist & Dr. Omar Morales, Transfusional Medicine, and active member reasercher of the Center for Nanoscience & Nanotechnology at UNAM. (National Autonomous University of Mexico)